STML - Stemline Therapeutics EPS beats by $0.14 beats on revenue August, 02 2019 07:03 AM Stemline Therapeutics Inc. Stemline Therapeutics (NASDAQ:STML): Q2 GAAP EPS of -$0.42 beats by $0.14.More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...